» Articles » PMID: 18468462

Human Effector and Memory CD8+ T Cell Responses to Smallpox and Yellow Fever Vaccines

Abstract

To explore the human T cell response to acute viral infection, we performed a longitudinal analysis of CD8(+) T cells responding to the live yellow fever virus and smallpox vaccines--two highly successful human vaccines. Our results show that both vaccines generated a brisk primary effector CD8(+) T cell response of substantial magnitude that could be readily quantitated with a simple set of four phenotypic markers. Secondly, the vaccine-induced T cell response was highly specific with minimal bystander effects. Thirdly, virus-specific CD8(+) T cells passed through an obligate effector phase, contracted more than 90% and gradually differentiated into long-lived memory cells. Finally, these memory cells were highly functional and underwent a memory differentiation program distinct from that described for human CD8(+) T cells specific for persistent viruses. These results provide a benchmark for CD8(+) T cell responses induced by two of the most effective vaccines ever developed.

Citing Articles

TGFβ links EBV to multisystem inflammatory syndrome in children.

Goetzke C, Massoud M, Frischbutter S, Guerra G, Ferreira-Gomes M, Heinrich F Nature. 2025; .

PMID: 40074901 DOI: 10.1038/s41586-025-08697-6.


Development of attenuated Orf virus as a safe oncolytic viral vector for nasopharyngeal carcinoma treatment.

Yamada Y, Wang Y, Liu H, Gerongano G, Tseng C, Liu S Virol J. 2025; 22(1):50.

PMID: 40001231 PMC: 11863438. DOI: 10.1186/s12985-025-02672-3.


Vaccine-induced T cell responses control Orthoflavivirus challenge infection without neutralizing antibodies in humans.

Kalimuddin S, Tham C, Chan Y, Hang S, Kunasegaran K, Chia A Nat Microbiol. 2025; 10(2):374-387.

PMID: 39794472 PMC: 11790491. DOI: 10.1038/s41564-024-01903-7.


Vaccines for cancer prevention: exploring opportunities and navigating challenges.

Graciotti M, Kandalaft L Nat Rev Drug Discov. 2024; 24(2):134-150.

PMID: 39622986 DOI: 10.1038/s41573-024-01081-5.


Advanced technologies for the development of infectious disease vaccines.

Gupta A, Rudra A, Reed K, Langer R, Anderson D Nat Rev Drug Discov. 2024; 23(12):914-938.

PMID: 39433939 DOI: 10.1038/s41573-024-01041-z.